Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study) - phase II data covering impact of concomitant hematological malignancies.
Roland LangTobias WelponerE RichtigI WolfC HoellerC HafnerV A NguyenJ KoflerM BartaP KoelblingerW HitzlM EmbergerM LaimerPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
This study demonstrated robust clinical efficacy of nivolumab in patients with locally advanced and metastatic cSCCs and a tolerability comparable to data of other anti-PD-1 antibodies. Favourable outcomes were obtained despite involving the oldest hitherto reported study cohort for anti-PD-1 antibodies and a significant proportion of CHM patients prone to high risk tumors and an aggressive course otherwise typically excluded from clinical trials.
Keyphrases
- squamous cell carcinoma
- clinical trial
- phase ii
- locally advanced
- small cell lung cancer
- open label
- end stage renal disease
- ejection fraction
- randomized controlled trial
- electronic health record
- neoadjuvant chemotherapy
- chronic kidney disease
- rectal cancer
- peritoneal dialysis
- deep learning
- patient reported outcomes